As of June 30, 2026, Coherus Oncology, Inc. carries a market capitalization of 193.71M, placing it among publicly traded companies globally. Its enterprise value stands at 136.24M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 193.71M |
| Enterprise Value | 136.24M |
Coherus Oncology, Inc.'s next confirmed earnings release is scheduled for March 15, 2027.
| Earnings Date | 3/15/2027 |
As of June 30, 2026, Coherus Oncology, Inc. has 154.47M shares outstanding.
| Shares Outstanding | 154.47M |
These figures are as of June 30, 2026. The price-to-sales ratio is 3.71, and the price-to-book ratio stands at 3.64.
| PS Ratio | 3.71 |
| PB Ratio | 3.64 |
| P/TBV Ratio | 13.96 |
| P/FCF Ratio | -1.02 |
| P/OCF Ratio | -1.02 |
These figures are as of June 30, 2026. The EV/Sales ratio of 3.06 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 136.24M versus a market cap of 193.71M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 3.06 |
As of June 30, 2026, Coherus Oncology, Inc. maintains a current ratio of 1.74, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 65.18, indicating elevated leverage, while an interest coverage ratio of -17.07 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.74 |
| Quick Ratio | 1.55 |
| Debt / Equity | 65.18 |
| Debt / EBITDA | -0.26 |
| Interest Coverage | -17.07 |
Over the twelve months ended June 30, 2026, Coherus Oncology, Inc. posted a negative return on equity (ROE) of -146.27, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -41.90, reflecting losses generated across the asset base. The company generates approximately 266,572.68 in revenue per employee across its workforce of 167.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.11 indicates how many times Coherus Oncology, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | -146.27 |
| Return on Assets (ROA) | -41.90 |
| Revenue Per Employee | 266,572.68 |
| Employee Count | 167.25 |
| Inventory Turnover | 3.11 |
As of the close on November 17, 2026, Coherus Oncology, Inc.'s stock has declined approximately 52.49% over the past 52 weeks. The 50-day moving average sits at 0.91, while the 200-day moving average is 1.25.
| 52-Week Price Change | -52.49% |
| 50-Day Moving Average | 0.91 |
| 200-Day Moving Average | 1.25 |
Over the twelve months ended June 30, 2026, Coherus Oncology, Inc. generated 44.58M in revenue and converted that into -115.66M in net income, yielding earnings per share of -1.07. EBITDA reached -135.75M, while operating income came in at -138.91M.
| Revenue | 44.58M |
| Gross Profit | 30.74M |
| Operating Income | -138.91M |
| Pretax Income | -141.05M |
| Net Income | -115.66M |
| EBITDA | -135.75M |
| EBIT | -138.91M |
| Earnings Per Share (EPS) | -1.07 |
As of June 30, 2026, Coherus Oncology, Inc. holds 92.17M in cash and equivalents against 34.71M in total debt, resulting in a net debt position of -39.98M. Total book value stands at 53.25M, with working capital of 49.71M providing operational flexibility.
| Cash & Cash Equivalents | 92.17M |
| Total Debt | 34.71M |
| Net Debt | -39.98M |
| Equity (Book Value) | 53.25M |
| Book Value Per Share | 0.34 |
| Working Capital | 49.71M |
Coherus Oncology, Inc. produced -162.83M in operating cash flow over the twelve months ended June 30, 2026.
| Operating Cash Flow | -162.83M |
| Free Cash Flow | -162.83M |
| FCF Per Share | -1.23 |
Over the twelve months ended June 30, 2026, Coherus Oncology, Inc. posted a gross margin of 68.94, reflecting its pricing power and cost economics. The operating margin of -311.56 and net profit margin of -259.41 provide insight into operational efficiency.
| Gross Margin | 68.94 |
| Operating Margin | -311.56 |
| Pretax Margin | -316.37 |
| Profit Margin | -259.41 |
| EBITDA Margin | -304.48 |
These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -98.41: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -27.93, meaning Coherus Oncology, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -27.93 |
| FCF Yield | -98.41 |
As of June 30, 2026, Coherus Oncology, Inc. has an Altman Z-Score of -15.56, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -15.56 |